Home > Dermatology > EADV 2022 > JAK3/TEC blockade leads to long-term improvement in alopecia areata

JAK3/TEC blockade leads to long-term improvement in alopecia areata

Presented By
Dr Athanasios Tsianakas, Fachklinik Bad Bentheim, Germany
Conference
EADV 2022
Trial
Phase 3, ALLEGRO-LT
The first long-term results of the JAK3/TEC kinase inhibitor ritlecitinib in alopecia areata (AA) were presented at EADV 2022. Ritlecitinib showed sustained efficacy over a treatment period up to month 36 with no new safety signals. Patient-reported outcomes improved already after a treatment phase of 3 months. Ritlecitinib is a selective inhibitor of JAK3 and the TEC kinase that previously showed efficacy in AA in the phase 2b/3 ALLEGRO study (NCT03732807) [1]. At this year´s EADV meeting, Dr Athanasios Tsianakas (Fachklinik Bad Bentheim, Germany) reported interim results from the de novo arm of ALLEGRO-LT (NCT04006457), an ongoing phase 3 study investigating the long-term safety and efficacy of ritlecitinib in patients with AA [2]. Included in the ALLEGRO-L...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on